Regulatory & availability trackers
The facts that move fastest — approval status, compounding legality, supply — held as dated, checkable statements rather than prose. Each point carries the date it was last confirmed against a primary source, and goes stale on a schedule if it isn't.
GLP-1 & Weight Loss
Approval status and clinical progress for the GLP-1 class.1 trackerTracking retatrutide — Eli Lilly's investigational triple GLP-1/GIP/glucagon receptor agonist — on its path to FDA approval. As of mid-2026 it remains in Phase 3 development and is not approved for any use.
Regulatory & Legal
Compounding legality and the shifting rules around peptide access.1 trackerThe legality of compounded semaglutide and tirzepatide has tightened sharply since both drugs came off the FDA shortage list. This tracks what is — and isn't — permitted now.
Availability
How and where patients can actually get these drugs right now.1 trackerHow patients actually access GLP-1 drugs in 2026 — from the new oral semaglutide pill to direct-to-patient cash-pay programs — as telehealth compounding routes narrow.
Inside a tracker
Compounded GLP-1 Legal Status · 4 points| Tracked statement | Status | Source | Last confirmed |
|---|---|---|---|
| Semaglutide shortage status — Removed from FDA shortage list (Feb 2025) | Expired | — | Sep 21, 2026 |
| Tirzepatide shortage status — Removed from FDA shortage list (Dec 2024) | Expired | — | Sep 21, 2026 |
| Compounding of semaglutide/tirzepatide — Broadly no longer permitted for mass production — Limited case-by-case compounding may remain for documented medical need under 503A; mass compounding ended. | Current | — | Sep 21, 2026 |
| Retatrutide / cagrilintide compounding — Not permitted — Not components of FDA-approved drugs. | Current | — | Sep 21, 2026 |
Expired does not mean false — it means nobody has confirmed it recently enough for us to stand behind it. 2 points here are past their window and are queued for review.